Filing excerpt
Biogen Inc. (Biogen) expects that its GAAP and non-GAAP results for the first quarter of 2026 will include acquired in-process research and development, upfront and milestone expense of approximately $34 million on a pre-tax basis.
What this signalsFilings often name leadership changes, deals and spending plans.
sec-8kmaterialContractGet every 8-K signal for Biogen and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Biogen this week?”
The Signal API returns 8-K signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-8k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/c449b5a9-b4ef-4c9f-a5e8-1cdd230df6c3 returns this record as JSON. POST /v1/companies/enrich returns every signal for biogen.com.
{
"signal_id": "c449b5a9-b4ef-4c9f-a5e8-1cdd230df6c3",
"signal_type": "sec-8k",
"signal_subtype": "materialContract",
"detected_at": "2026-04-07T09:30:39.907+00:00",
"company": {
"name": "Biogen",
"domain": "biogen.com"
},
"data": {
"detail": "Biogen is actively investing in external innovation through collaboration, licensing, and R&D asset acquisitions, signaling available budget for strategic projects. This spending creates opportunities for vendors supporting clinical development, M&A due diligence, and partnership management.",
"metrics": {
"timeframe": "current_quarter",
"dollar_context": "Acquired in-process research and development, upfront and milestone expense",
"dollar_millions": 34
},
"summary": "Biogen to incur $34M in Q1 expenses for R&D collaborations and asset acquisitions.",
"excerpts": "Biogen Inc. (Biogen) expects that its GAAP and non-GAAP results for the first quarter of 2026 will include acquired in-process research and development, upfront and milestone expense of approximately $34 million on a pre-tax basis.",
"relevance": 0.8,
"sentiment": "positive",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/875045/000087504526000039/biib-20260406.htm",
"filing_date": "2026-04-06",
"filing_year": 2026,
"fiscal_year_end": "04/06",
"sales_relevance": "Vendor relationship signal",
"signal_category": "strategic"
}
}
curl https://signals.autobound.ai/v1/signals/c449b5a9-b4ef-4c9f-a5e8-1cdd230df6c3 \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"biogen.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.